WO2000076556A3 - High dose radionuclide complexes for bone marrow suppression - Google Patents

High dose radionuclide complexes for bone marrow suppression Download PDF

Info

Publication number
WO2000076556A3
WO2000076556A3 PCT/US2000/016052 US0016052W WO0076556A3 WO 2000076556 A3 WO2000076556 A3 WO 2000076556A3 US 0016052 W US0016052 W US 0016052W WO 0076556 A3 WO0076556 A3 WO 0076556A3
Authority
WO
WIPO (PCT)
Prior art keywords
bone marrow
diseases
high dose
marrow suppression
radionuclide complexes
Prior art date
Application number
PCT/US2000/016052
Other languages
French (fr)
Other versions
WO2000076556A9 (en
WO2000076556A2 (en
Inventor
Paul G Abrams
Lauren M Tatalick
Kent R Thoelke
James Kyle Bryan
Elizabeth K John
Mark D Hylarides
Alan R Fritzberg
Original Assignee
Neorx Corp
Paul G Abrams
Lauren M Tatalick
Kent R Thoelke
James Kyle Bryan
Elizabeth K John
Mark D Hylarides
Alan R Fritzberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU58710/00A priority Critical patent/AU5871000A/en
Priority to CA002371728A priority patent/CA2371728C/en
Priority to EP00944644A priority patent/EP1191948A2/en
Priority to JP2001502887A priority patent/JP2003501488A/en
Application filed by Neorx Corp, Paul G Abrams, Lauren M Tatalick, Kent R Thoelke, James Kyle Bryan, Elizabeth K John, Mark D Hylarides, Alan R Fritzberg filed Critical Neorx Corp
Publication of WO2000076556A2 publication Critical patent/WO2000076556A2/en
Publication of WO2000076556A3 publication Critical patent/WO2000076556A3/en
Publication of WO2000076556A9 publication Critical patent/WO2000076556A9/en
Priority to US10/014,335 priority patent/US6767531B2/en
Priority to US10/601,081 priority patent/US7094885B2/en
Priority to US10/784,476 priority patent/US7097823B2/en
Priority to US10/882,054 priority patent/US7408046B2/en
Priority to US11/041,828 priority patent/US7070759B2/en
Priority to US11/359,744 priority patent/US7605239B2/en
Priority to US11/485,183 priority patent/US7378077B2/en
Priority to US12/043,757 priority patent/US7691985B2/en
Priority to US12/142,664 priority patent/US7696331B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Abstract

The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.
PCT/US2000/016052 1999-06-11 2000-06-12 High dose radionuclide complexes for bone marrow suppression WO2000076556A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
AU58710/00A AU5871000A (en) 1999-06-11 2000-06-12 High dose radionuclide complexes for bone marrow suppression
CA002371728A CA2371728C (en) 1999-06-11 2000-06-12 High dose radionuclide complexes for bone marrow suppression
EP00944644A EP1191948A2 (en) 1999-06-11 2000-06-12 High dose radionuclide complexes for bone marrow suppression
JP2001502887A JP2003501488A (en) 1999-06-11 2000-06-12 High-dose radionuclide complexes for bone marrow suppression
US10/014,335 US6767531B2 (en) 1999-07-11 2001-12-11 High dose radionuclide complexes for bone marrow suppression
US10/601,081 US7094885B2 (en) 1999-07-11 2003-06-20 Skeletal-targeted radiation to treat bone-associated pathologies
US10/784,476 US7097823B2 (en) 1999-07-11 2004-02-23 High dose radionuclide complexes for bone marrow suppression
US10/882,054 US7408046B2 (en) 1999-07-11 2004-06-30 Treatment of bone-associated cancers
US11/041,828 US7070759B2 (en) 1999-07-11 2005-01-24 High dose radionuclide complexes for bone marrow suppression
US11/359,744 US7605239B2 (en) 1999-07-11 2006-02-22 Skeletal-targeted radiation to treat bone-associated pathologies
US11/485,183 US7378077B2 (en) 1999-07-11 2006-07-12 High dose radionuclide complexes for bone marrow suppression
US12/043,757 US7691985B2 (en) 1999-07-11 2008-03-06 Skeletal-targeted radiation to treat bone-associated pathologies
US12/142,664 US7696331B2 (en) 1999-07-11 2008-06-19 High dose radionuclide complexes for bone marrow treatment

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US60/139,065 1999-06-11
US13906599P 1999-07-11 1999-07-11
US14378099P 1999-07-13 1999-07-13
US60/143,780 1999-07-13
US14982199P 1999-08-19 1999-08-19
US60/149,821 1999-08-19

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/014,335 Continuation US6767531B2 (en) 1999-07-11 2001-12-11 High dose radionuclide complexes for bone marrow suppression

Publications (3)

Publication Number Publication Date
WO2000076556A2 WO2000076556A2 (en) 2000-12-21
WO2000076556A3 true WO2000076556A3 (en) 2001-10-11
WO2000076556A9 WO2000076556A9 (en) 2001-11-08

Family

ID=27385279

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/016052 WO2000076556A2 (en) 1999-06-11 2000-06-12 High dose radionuclide complexes for bone marrow suppression

Country Status (6)

Country Link
US (6) US6767531B2 (en)
EP (1) EP1191948A2 (en)
JP (1) JP2003501488A (en)
AU (1) AU5871000A (en)
CA (1) CA2371728C (en)
WO (1) WO2000076556A2 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2371728C (en) * 1999-06-11 2009-06-02 Neorx Corporation High dose radionuclide complexes for bone marrow suppression
US7094885B2 (en) * 1999-07-11 2006-08-22 Neorx Corporation Skeletal-targeted radiation to treat bone-associated pathologies
WO2001091806A2 (en) * 2000-05-31 2001-12-06 Steven Mccullough Measurement of the therapeutic dose for bone marrow ablation therapy
NO313180B1 (en) * 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Visiting alpha particles emitting radiopharmaceuticals
WO2002062398A2 (en) * 2001-01-08 2002-08-15 Neorx Corporation Radioactively labelled conjugates of phosphonates
US7045116B2 (en) 2001-12-13 2006-05-16 Dow Global Technologies Inc. Treatment of osteomyelitis with radiopharmaceuticals
CA2509328A1 (en) * 2002-12-10 2004-06-24 University Of Miami Radioablation of hemolymphopoietic cell populations
EP1475105A1 (en) * 2003-05-09 2004-11-10 Schering AG Bone localising radiopharmaceutical and tubulin-interacting compound combinatorial radiotherapy
US20070092440A1 (en) * 2003-05-09 2007-04-26 Edgar Braendle Bone localising radiopharmaceutical and tubulin-interacting compound combinatorial
WO2007008232A2 (en) * 2004-09-03 2007-01-18 Board Of Regents, The University Of Texas System Locoregional internal radionuclide ablation of abnormal tissues.
US8709380B1 (en) * 2006-02-07 2014-04-29 Sirius Medicine, Llc Targeting agents for enhancing radiation therapy
WO2007126730A1 (en) * 2006-03-29 2007-11-08 Isotherapeautics Group Llc Radionuclide therapy for urinary bladder cancer
WO2008060663A2 (en) * 2006-04-14 2008-05-22 Thorenco, Llc Compact neutron generator for medical and commercial isotope production, fission product purification and controlled gamma reactions for direct electric power generation
US8198264B2 (en) * 2006-04-28 2012-06-12 National Cancer Center Method for treating head and neck cancer
TW200809194A (en) * 2006-05-04 2008-02-16 Wyeth Corp Determination of antibiotic concentration in bone
ATE510536T1 (en) * 2006-08-16 2011-06-15 Action Medicines Sl USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF REACTIVE TISSUE DISEASES
US9993437B2 (en) 2007-12-06 2018-06-12 The Regents Of The University Of California Mesoporous silica nanoparticles for biomedical applications
US20100310465A1 (en) * 2008-01-23 2010-12-09 The Regents Of The University Of California Nano-devices having releasable seals for controlled release of molecules
WO2010011927A1 (en) 2008-07-25 2010-01-28 Noventis, Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
WO2010078569A2 (en) * 2009-01-05 2010-07-08 Stc.Unm Porous nanoparticle supported lipid bilayer nanostructures
CN102316901B (en) * 2009-02-18 2013-09-11 久光制药株式会社 Transdermal preparation
US20120207795A1 (en) * 2010-07-13 2012-08-16 The Regents Of The University Of California Cationic polymer coated mesoporous silica nanoparticles and uses thereof
EP2595636A4 (en) 2010-07-22 2014-01-15 Reven Pharmaceuticals Inc Methods of treating or ameliorating diseases and enhancing performance comprising the use of a magnetic dipole stabilized solution
EP2701686A4 (en) 2011-04-28 2014-11-05 Stc Unm Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery and methods of using same
US10220004B2 (en) 2011-07-14 2019-03-05 The Regents Of The University Of California Method of controlled delivery using sub-micron-scale machines
HUE062439T2 (en) * 2013-10-07 2023-11-28 Igl Pharma Inc Process for preparing high purity therapeutic bone agents
RU2599874C2 (en) * 2014-10-13 2016-10-20 Михаил Сергеевич АНОСОВ Method of treatment of chronic odontogenic osteomyelitis in drug-addicts patients
US11369700B2 (en) 2015-05-25 2022-06-28 IGL Pharma Inc. DOTMP kit formulations for radioisotopes
WO2016191413A1 (en) 2015-05-25 2016-12-01 Iso Therapeutics Group, Llc Dotmp kit formulations for radioisotopes
IL290251B1 (en) * 2015-12-07 2024-03-01 General Oncology Inc Combination for the effective treatment of metastatic cancer in patients
US11672866B2 (en) 2016-01-08 2023-06-13 Paul N. DURFEE Osteotropic nanoparticles for prevention or treatment of bone metastases
US11344629B2 (en) 2017-03-01 2022-05-31 Charles Jeffrey Brinker Active targeting of cells by monosized protocells
US10093741B1 (en) 2017-05-05 2018-10-09 Fusion Pharmaceuticals Inc. IGF-1R monoclonal antibodies and uses thereof
CA3062553C (en) 2017-05-05 2024-02-06 Fusion Pharmaceuticals Inc. Pharmacokinetic enhancements of bifunctional chelates and uses thereof
US11433148B2 (en) 2017-05-05 2022-09-06 Centre For Probe Development And Commercialization IGF-1R monoclonal antibodies and uses thereof
CR20200291A (en) 2017-12-07 2020-11-18 Reven Ip Holdco Llc Compositions and methods for the treatment of metabolic conditions
WO2020092259A1 (en) * 2018-10-29 2020-05-07 Molecular Stethoscope, Inc. Characterization of bone marrow using cell-free messenger-rna
CN114222566A (en) * 2019-06-12 2022-03-22 雷文知识产权控股有限公司 Methods and compositions for improving outcome in cancer patients
WO2021154746A1 (en) 2020-01-28 2021-08-05 Reflexion Medical, Inc. Joint optimization of radionuclide and external beam radiotherapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2230374A1 (en) * 1973-05-23 1974-12-20 Procter & Gamble Phosphonates contg. a P-32 or P-33 radionuclide - prepd. by reaction of labelled phosphorus trichloride and acid
WO1991016075A1 (en) * 1990-04-20 1991-10-31 Australian Nuclear Science & Technology Organisation Bone marrow treatments

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US587451A (en) * 1897-08-03 James douglas o neill
US158393A (en) * 1875-01-05 Improvement in grates
US589190A (en) * 1897-08-31 Apparatus for compressing air
US410436A (en) * 1889-09-03 packham
US118508A (en) * 1871-08-29 Improvement in flour-bolts
US96393A (en) * 1869-11-02 Improved furniture-caster
US470753A (en) * 1892-03-15 William grunow
US716818A (en) * 1901-04-13 1902-12-23 James A Ekin Criswell Machine for making matches.
US937333A (en) * 1909-06-26 1909-10-19 William H Shugart Rail-joint.
GB750155A (en) * 1953-03-17 1956-06-13 Nat Res Dev Substituted alanines
US3032585A (en) * 1954-12-03 1962-05-01 Nat Res Dev Process for the production of p-bis-(2-chloroethyl)-aminophenylalanine
US3398097A (en) * 1965-07-30 1968-08-20 Progressive Products Co Cleaning composition, and method of cleaning and sequestering metal ions
BE744394A (en) * 1970-01-14 1970-07-14 Elphiac Sa Zone refining process
US3726912A (en) * 1970-07-02 1973-04-10 Dow Chemical Co Substituted alkanolamine chelating agents
US3989730A (en) * 1972-06-15 1976-11-02 Research Corporation Bone-seeking technetium-99m complex
US3852414A (en) * 1972-09-13 1974-12-03 New England Nuclear Corp Bone seeking technetium 99m stannous phosphate complex
US3965254A (en) * 1973-05-23 1976-06-22 The Procter & Gamble Company Compositions for the treatment of calcific tumors
US3931396A (en) * 1973-05-31 1976-01-06 Commissariat A L'energie Atomique Method of preparation of a composition having a base of 99m technetium for diagnosis by scintigraphy
US4058704A (en) * 1974-12-27 1977-11-15 Taeo Kim Coilable and severable heating element
US4017596A (en) * 1975-03-03 1977-04-12 Research Corporation Radiopharmaceutical chelates and method of external imaging
US3974268A (en) * 1975-05-30 1976-08-10 Research Corporation Bone-seeking technetium-99m imidodiphosphonate complex
DE2543349C2 (en) 1975-09-29 1984-05-10 Henkel KGaA, 4000 Düsseldorf Preparations for the production of 99m technetium-radiagnostica
US4075314A (en) * 1976-04-29 1978-02-21 Mallinckrodt, Inc. Stannous pyrophosphate technetium-99m compositions
CA1078731A (en) 1976-12-16 1980-06-03 Charles E. Frosst And Co. Skeletal imaging kit utilizing triethylene tetramine hexa (methylene phosphonic acid)
US4399817A (en) * 1981-06-30 1983-08-23 The Procter & Gamble Company Boron containing polyphosphonates for the treatment of calcific tumors
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4647447A (en) * 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4508625A (en) * 1982-10-18 1985-04-02 Graham Marshall D Magnetic separation using chelated magnetic ions
US4707353A (en) * 1982-12-08 1987-11-17 Mallinckrodt, Inc. Radiographic imaging agents
DE3247054C1 (en) * 1982-12-20 1984-05-10 Goetze Ag, 5093 Burscheid Spray powder for the production of wear-resistant coatings
SE8301395L (en) * 1983-03-15 1984-09-16 Wallac Oy KELATIZING COMPOUNDS WITH FUNCTIONAL GROUPS WHICH ALLOW COVALENT COUPLING TO BIO-ORGANIC MOLECULES
US4515767A (en) * 1983-06-20 1985-05-07 The Dow Chemical Company Radioactive metals complexed with phosphonate derivatives of dicyclopentadienebis(methylamine)
US4676950A (en) * 1984-02-03 1987-06-30 Foster Research Corporation Indicator and test device for detecting occult blood
US4560548A (en) * 1984-04-10 1985-12-24 The Dow Chemical Company Bone seeking Tc-99m complexes of phosphonate derivatives of bis(aminoalkyl)piperazine
AU563671B2 (en) 1984-06-04 1987-07-16 Dow Chemical Company, The Organic amine phosphonic acid complexes
US5059412A (en) 1984-06-04 1991-10-22 The Dow Chemical Company Macrocyclic aminophosphonic acid complexes for the treatment of calcific tumors
US4898724A (en) * 1984-06-04 1990-02-06 The Dow Chemical Company Organis amine phosphonic acid complexes for the treatment of calcific tumors
US5064633A (en) * 1984-06-04 1991-11-12 The Dow Chemical Company Macrocyclic aminophosphonic acid complexes, their formulations and use
US5066478A (en) * 1984-06-04 1991-11-19 The Dow Chemical Company Radio labeled organic amine phosphonic acid complexes for the treatment of calcific tumors
US4606907A (en) * 1984-07-02 1986-08-19 The Dow Chemical Company Bone seeking Tc-99m complexes of phosphonate derivatives of polyamidoamines
US4897254A (en) * 1984-09-21 1990-01-30 The Dow Chemical Company Radioactive compositions for the treatment of calcific tumors
US4639365A (en) * 1984-10-18 1987-01-27 The Board Of Regents, The University Of Texas System Gadolinium chelates as NMR contrast agents
US4678687A (en) * 1984-10-31 1987-07-07 Xerox Corporation Thermal transfer printing sheets containing certain coating compositions thereof
US5556982A (en) 1985-01-14 1996-09-17 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US4897255A (en) 1985-01-14 1990-01-30 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US5393512A (en) 1985-01-14 1995-02-28 Vanderheyden; Jean-Luc Stable therapeutic radionuclide compositions and methods for preparation thereof
US5288497A (en) * 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US4752464A (en) * 1985-06-07 1988-06-21 Cadema Medical Products, Inc. Treatment of arthritis, including rheumatoid arthritis, with radioactive isotopes
US4678667A (en) * 1985-07-02 1987-07-07 501 Regents of the University of California Macrocyclic bifunctional chelating agents
GB8518300D0 (en) 1985-07-19 1985-08-29 Amersham Int Plc Contrast agent
DE3772785D1 (en) 1986-01-23 1991-10-17 Squibb & Sons Inc 1-SUBSTITUTED-4,7,10-TRISCARBOXYMETHYL-1,4,7,10-TETRAAZACYCLODODECAN AND ANALOG.
US4885363A (en) * 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
DE3625417C2 (en) 1986-07-28 1998-10-08 Schering Ag Tetraazacyclododecane derivatives
AU608759B2 (en) 1986-08-04 1991-04-18 Amersham Health Salutar Inc NMR imaging with paramagnetic polyvalents metal salts of poly-(acid-alkylene-amido)-alkanes
FR2614020B1 (en) 1987-04-14 1989-07-28 Guerbet Sa NOVEL NITROGEN CYCLIC LIGANDS, METAL COMPLEXES FORMED BY SUCH LIGANDS, DIAGNOSTIC COMPOSITIONS CONTAINING THESE COMPLEXES AND PROCESS FOR PREPARING LIGANDS.
US4853209A (en) * 1987-05-18 1989-08-01 The Dow Chemical Company Bone marrow suppressing agents
US5202109A (en) * 1988-06-10 1993-04-13 Neorx Corporation Conjugates for bone imaging and bone cancer therapy
US5089249A (en) * 1988-06-10 1992-02-18 Neorx Corporation Conjugates for bone imaging and bone cancer therapy
US4882142A (en) * 1988-12-19 1989-11-21 The Dow Chemical Company Bone marrow suppressing agents
US4937333A (en) 1989-08-04 1990-06-26 The Dow Chemical Company Method for purifying aminomethylenephosphonic acids for pharmaceutical use
US4976950A (en) 1988-12-19 1990-12-11 The Dow Chemical Company Bone marrow suppressing agents
GB8903023D0 (en) 1989-02-10 1989-03-30 Parker David Chemical compounds
US5714467A (en) * 1989-04-12 1998-02-03 The Rockefeller University Antibacterial and antimalarial hybrid peptides
GB9002375D0 (en) * 1990-02-02 1990-04-04 Pfizer Ltd Triazole antifungal agents
US5064433A (en) * 1990-03-05 1991-11-12 Helix Medical, Inc. Voice prosthesis insertion assemblies
DE69124132T2 (en) 1990-04-18 1997-06-05 Celltech Therapeutics Ltd Tetra-aza macrocycles, processes for their preparation and their use in NMR imaging
DE59104720D1 (en) * 1990-06-15 1995-03-30 Hoechst Ag ANTIFUNGIC POLYPEPTIDE, METHOD FOR THE PRODUCTION THEREOF.
MC2260A1 (en) * 1990-06-18 1993-04-26 Dow Chemical Co RADIOPHARMACEUTICAL FORMULATIONS, THEIR METHOD OF ADMINISTRATION AND THEIR PREPARATION PROCESS
US5219556A (en) * 1990-07-09 1993-06-15 Mallinckrodt Medical, Inc. Stabilized therapeutic radiopharmaceutical complexes
RU2051919C1 (en) * 1990-08-20 1996-01-10 Сантори Лимитед Penem compounds and pharmaceutical composition on their base
US5286497A (en) * 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
US5861430A (en) * 1991-12-17 1999-01-19 Jasmine Fockerman Benzopyran phenol derivates for use as antibacterial, antiviral or immunostimulating agents
US5919925A (en) * 1992-01-22 1999-07-06 Pfizer Inc. 2-isocephem and oxacephem derivatives and use as antibacterial agents
JPH07507804A (en) * 1992-06-09 1995-08-31 ネオルックス　コーポレーション Pre-targeting methods and compounds
CA2086874E (en) * 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
KR100296414B1 (en) * 1992-10-28 2001-10-24 로버트 엘. 입센 Antibacterial Mouthwash
US5714604A (en) * 1993-05-06 1998-02-03 The Dow Chemical Company Process for the preparation of azamacrocyclic or acyclic aminophosphonate ester derivatives
SE9301830D0 (en) * 1993-05-28 1993-05-28 Ab Astra NEW COMPOUNDS
MX9406466A (en) * 1993-08-24 1997-02-28 Janssen Pharmaceutica Nv Antibacterial and antifouling oxathiazines and their oxides.
US5587451A (en) 1993-11-26 1996-12-24 The Dow Chemical Company Process for preparing polyazamacrocycles
FR2719481B1 (en) * 1994-05-05 1996-05-31 Oreal Composition based on antifungal compounds and halogenated antibacterial compounds to reduce hair loss.
WO1996012704A1 (en) * 1994-10-20 1996-05-02 Wakunaga Seiyaku Kabushiki Kaisha Novel pyridonecarboxylate derivative or salt thereof and antibacterial containing the same as active ingredient
CN1056849C (en) * 1994-11-08 2000-09-27 葛兰素惠尔康有限公司 Carbocyclic compound
AU3696495A (en) * 1994-11-17 1996-06-17 F. Hoffmann-La Roche Ag Antibacterial dibenzimidazole derivatives
DE69526958T2 (en) * 1994-11-29 2003-01-16 Hisamitsu Pharmaceutical Co ANTIBACTERIAL OR BACTERICIDE AGENTS CONTAINING 2-AMINOTHIAZOLE DERIVATIVES AND THEIR SALTS
US5773421A (en) * 1995-01-10 1998-06-30 Abbott Laboratories Antifungal fusacandins
PT805685E (en) * 1995-01-26 2002-02-28 Merck & Co Inc NEW CYCLE-HEXAPEPTIDEOS ANTI-FUNGICOS
CN1173898A (en) * 1995-02-08 1998-02-18 株式会社植物防御系统研究所 Antifungal torpene compounds and process for produing the same
JP3081773B2 (en) * 1995-03-31 2000-08-28 株式会社資生堂 N-acylpiperazine derivatives and antibacterial and antiulcer agents
US5786325A (en) * 1995-05-26 1998-07-28 Eli Lilly And Company Cyclic peptide antifungal agents and methods of making and using
MX9702380A (en) * 1995-08-02 1998-02-28 Uriach & Cia Sa J New carboxamides with antifungal activity.
PT783501E (en) * 1995-08-02 2001-04-30 Uriach & Cia Sa J PYRIMIDONE DERIVATIVES WITH ANTIFUNGAL ACTIVITY
US5681430A (en) * 1995-08-23 1997-10-28 Thermo Fibertek Inc. Activity induction in papermaking
US5872249A (en) * 1995-09-01 1999-02-16 Korea Institute Of Science And Technology 3-ammoniopropenyl cephalosporin compounds as antibacterial agents and process for preparing the same
DE69625238T2 (en) * 1995-09-15 2003-07-24 Upjohn Co ALPHA, BETA-SATURATED AND UNSATURATED 3-ARYL-5-AMINOMETHYL-BUTYROLACTONE ANTIBACTERIAL AGENTS
WO1997009878A1 (en) * 1995-09-15 1997-03-20 Scriptgen Pharmaceuticals, Inc. Arylhydrazone derivatives useful as antibacterial agents
US5837726A (en) * 1995-11-01 1998-11-17 Millennium Pharmaceuticals, Inc. Antifungal agents derived from aspergillus fumigatus
EP0781566B1 (en) * 1995-12-26 2004-07-28 Toyo Boseki Kabushiki Kaisha Organic solvent-soluble mucopolysaccharide, antibacterial antithrombogenic composition and medical material
US5756472A (en) * 1996-01-31 1998-05-26 Merck & Co., Inc. Antifungal agent obtained from hormonema
JP4058129B2 (en) * 1996-03-18 2008-03-05 株式会社資生堂 Pyridine derivatives and anti-ulcer agents, antibacterial agents
US5770617A (en) * 1996-03-20 1998-06-23 Rutgers, The State University Of New Jersey Terbenzimidazoles useful as antifungal agents
US5773696A (en) * 1996-03-29 1998-06-30 Monsanto Company Antifungal polypeptide and methods for controlling plant pathogenic fungi
JP3693449B2 (en) * 1996-04-05 2005-09-07 三菱製紙株式会社 Antibacterial antifungal agent and fibrous substance containing the same
JP4150435B2 (en) * 1996-04-18 2008-09-17 株式会社資生堂 Alkylene diamine derivatives and anti-ulcer agents, antibacterial agents
US5756725A (en) * 1996-04-24 1998-05-26 Merck & Co., Inc. Carbapenem antibacterial compounds, compositions containing such compounds and methods of treatment
US5917084A (en) * 1996-07-03 1999-06-29 Millennium Pharmaceuticals, Inc. Antifungal agents
GB2315489A (en) * 1996-07-17 1998-02-04 Merck & Co Inc Antifungal agent
US5837253A (en) * 1996-07-26 1998-11-17 Agrogene Ltd. Preparation and use of Inula extracts as a fungicide for the control of plant diseases
US5908862A (en) * 1996-07-31 1999-06-01 Abbot Laboratories Water-miscible esters of mono--and diglycerides having antibacterial activity and their use in inhibiting infection
UA51730C2 (en) * 1996-09-04 2002-12-16 Ебботт Лабораторіз 6-0-substituted ketolides having antibacterial activity
US5830855A (en) * 1996-09-12 1998-11-03 Utah State University Lipodepsipeptides as antifungal and fungicidal agents
US5876738A (en) * 1996-10-29 1999-03-02 Toagosei Co., Ltd. Antifungal phyllosilicate
US6005083A (en) 1997-03-28 1999-12-21 Neorx Corporation Bridged aromatic substituted amine ligands with donor atoms
JP4090087B2 (en) * 1997-04-04 2008-05-28 株式会社資生堂 Benzamide derivatives and anti-ulcer agents, antibacterial agents
US5863773A (en) * 1997-09-30 1999-01-26 Abbott Laboratories Antifungal corynecandin
DE19911329A1 (en) * 1998-03-27 2000-09-21 Benes Ivan Friedrich Radioimmunoconjugate which can be used in human therapy and process for its preparation
CA2371728C (en) * 1999-06-11 2009-06-02 Neorx Corporation High dose radionuclide complexes for bone marrow suppression
US7094885B2 (en) * 1999-07-11 2006-08-22 Neorx Corporation Skeletal-targeted radiation to treat bone-associated pathologies
WO2002062398A2 (en) * 2001-01-08 2002-08-15 Neorx Corporation Radioactively labelled conjugates of phosphonates
US7045116B2 (en) * 2001-12-13 2006-05-16 Dow Global Technologies Inc. Treatment of osteomyelitis with radiopharmaceuticals

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2230374A1 (en) * 1973-05-23 1974-12-20 Procter & Gamble Phosphonates contg. a P-32 or P-33 radionuclide - prepd. by reaction of labelled phosphorus trichloride and acid
WO1991016075A1 (en) * 1990-04-20 1991-10-31 Australian Nuclear Science & Technology Organisation Bone marrow treatments

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
BAYOUTH J E ET AL: "Radiation dose distribution within the bone marrow of patients receiving holmium-166-labeled-phosphonate for marrow ablation.", MEDICAL PHYSICS (NEW YORK), vol. 22, no. 6, 1995, pages 743 - 753, XP000990163, ISSN: 0094-2405 *
BAYOUTH JOHN E ET AL: "Pharmacokinetics, dosimetry and toxicity of holmium-166-DOTMP for bone marrow ablation in multiple myeloma.", JOURNAL OF NUCLEAR MEDICINE, vol. 36, no. 5, May 1995 (1995-05-01), pages 730 - 737, XP000990469, ISSN: 0161-5505 *
CHAMPLIN R ET AL: "Holmium-166 DOTMP, a bone seeking radiochelate for selective marrow radiotherapy with bone marrow transplantation (BMT) for multiple myeloma.", BLOOD, vol. 82, no. 10, suppl. 1, 1993, & Thirty-fifth Annual Meeting of the American Society of Hematology;St. Louis, Missouri, USA; December 3-7, 1993, pages 266A, abstract no. 1051,, XP000990167, ISSN: 0006-4971 *
HASSFJELL S P ET AL: "212Bi-DOTMP: An alpha particle emitting bone-seeking agent for targeted radiotherapy.", NUCLEAR MEDICINE AND BIOLOGY, vol. 24, no. 3, 1997, pages 231 - 237, XP000990472, ISSN: 0969-8051 *
KASI L P ET AL: "Holmium-166 DOTMP: A new agent for bone marrow ablation.", JOURNAL OF NUCLEAR MEDICINE, vol. 34, no. 5 (suppl.), 1993, & 40th Annual Meeting of the Society of Nuclear Medicine;Toronto, Ontario, Canada; June 8-11, 1993, pages 33P, abstract no. 125,, XP000990465, ISSN: 0161-5505 *
MCCULLOUGH S P ET AL: "Non-target organ doses in patients undergoing bone marrow ablation with Ho-166-DOTMP.", JOURNAL OF NUCLEAR MEDICINE, vol. 39, no. 5 (suppl), May 1998 (1998-05-01), & 45th Annual Meeting of the Society of Nuclear Medicine;Toronto, Ontario, Canada; June 7-11, 1998, pages 186P, abstract no. 838, XP000990467, ISSN: 0161-5505 *
MCCULLOUGH S P ET AL: "Pharmacokinetics and patient specific dosimetry of high dose 166Ho-DOTMP therapy used for treatment of breast cancer metastatic to bone.", JOURNAL OF NUCLEAR MEDICINE, vol. 40, no. 5 (suppl.), May 1999 (1999-05-01), & 46th Annual Meeting of the Society of Nuclear Medicine;Los Angeles, California, USA; June 6-10, 1999, pages 40P, abstract no. 160,, XP000990463, ISSN: 0161-5505 *
PARKS N J ET AL: "Bone marrow transplantation in dogs after radioablation with a new Ho-166 amino phosphonic acid bone-seeking agent (DOTMP).", BLOOD, vol. 82, no. 1, 1993, pages 318 - 325, XP000990166, ISSN: 0006-4971 *
PODOLOFF D A ET AL: "Phase I/II study of holmium-166-DOTMP for bone marrow ablation in multiple myeloma prior to bone marrow transplantation (BMT).", JOURNAL OF NUCLEAR MEDICINE, vol. 35, no. 5 (supppl.), 1994, & 41st Annual Meeting of the Society of Nuclear Medicine;Orlando, Florida, USA; June 5-8, 1994, pages 37P, abstract no. 139,, XP000990466, ISSN: 0161-5505 *
PODOLOFF D A ET AL: "Update on the Ho-166 DOTMP bone marrow ablation trial at U.T.M.D. Anderson Cancer Center.", JOURNAL OF NUCLEAR MEDICINE, vol. 37, no. 5 (suppl.), 1996, & 43rd Annual Meeting of the Society of Nuclear Medicine;Denver, Colorado, USA; June 3-5, 1996, pages 234P, abstract no. 1053, XP000990464, ISSN: 0161-5505 *
TURNER J H ET AL: "SAMARIUM-153 EDTMP AND MELPHALAN CHEMORADIOTHERAPY REGIMEN FOR BONE MARROW ABLATION PRIOR TO MARROW TRANSPLANTATION AN EXPERIMENTAL MODEL IN THE RAT", NUCLEAR MEDICINE COMMUNICATIONS, vol. 13, no. 5, 1992, pages 321 - 329, XP000990160, ISSN: 0143-3636 *
TURNER J H ET AL: "Samarium-153 EDTMP and melphalan chemoradiotherapy regimen for bone marrow ablation prior to marrow transplantation in the C57Bl/KaLwRij mouse as a model for treatment of multiple myeloma.", AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, vol. 22, no. 4, 1992, 23rd Annual Scientific Meeting of the Australian and New Zealand Society of Nuclear Medicine;Adelaide, South Australia, Australia; May 3-6, 1992, pages 405, XP000990161, ISSN: 0004-8291 *
TURNER J HARVEY ET AL: "Radiopharmaceutical therapy of 5T33 murine myeloma by sequential treatment with samarium-153 ethylenediaminetetramethylene phosphonate, melphalan, and bone marrow transplantation.", JOURNAL OF THE NATIONAL CANCER INSTITUTE (BETHESDA), vol. 85, no. 18, 1993, pages 1508 - 1513, XP000990170, ISSN: 0027-8874 *

Also Published As

Publication number Publication date
US20070053833A1 (en) 2007-03-08
EP1191948A2 (en) 2002-04-03
US7070759B2 (en) 2006-07-04
AU5871000A (en) 2001-01-02
US20050129667A1 (en) 2005-06-16
US20050238578A1 (en) 2005-10-27
JP2003501488A (en) 2003-01-14
US6767531B2 (en) 2004-07-27
US20090136419A1 (en) 2009-05-28
WO2000076556A9 (en) 2001-11-08
US20050063905A1 (en) 2005-03-24
US7408046B2 (en) 2008-08-05
WO2000076556A2 (en) 2000-12-21
CA2371728C (en) 2009-06-02
US20020176818A1 (en) 2002-11-28
US7097823B2 (en) 2006-08-29
CA2371728A1 (en) 2000-12-21
US7378077B2 (en) 2008-05-27
US7696331B2 (en) 2010-04-13

Similar Documents

Publication Publication Date Title
WO2000076556A3 (en) High dose radionuclide complexes for bone marrow suppression
WO2001024763A3 (en) Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
WO2000053730A3 (en) Medical preparations for the treatment of alpha-galactosidase a deficiency
IE940833L (en) Macrocyclic aminophosphonic acid complexes, their¹preparation, formulations and use
HK1197656A1 (en) Treatment of glycogen storage disease type ii ii
NZ337527A (en) Water-soluble pharmaceutical composition comprising an ionic complex of a polypeptide and an amphiphilic compound and a method for increasing the activity of a polypeptide by forming the aforementioned complex
HK1053115A1 (en) Quinazoline derivatives for the treatment of tumours.
WO2001072721A3 (en) Synergistic methods and compositions for treating cancer
EP1024145A3 (en) Novel azalides and methods of making same
WO2002085299A3 (en) Therapeutic treatments using the direct application of antimicrobial metal compositions
EP0943331A3 (en) Formulations containing oxaliplatin
YU3902A (en) Imidazoimidiazoles and triazoles as anti-inflamatory agents
MXPA03007837A (en) Compositions for delivering bisphosphonates.
EP1100522A4 (en) Pulmonary delivery of active agents
AU2002236765A1 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
CA2003326A1 (en) Bone marrow suppressing agents
WO2005030753A3 (en) Therapeutic agents useful for treating pain
EP1392328A4 (en) Cancer therapy
AU4258101A (en) Combination therapies with vascular damaging activity
NZ511172A (en) Buffered compositions for dialysis
EP0281070A3 (en) Pharmaceutical composition for the treatment of cancer
WO2003053365A3 (en) Syn3 compositions and methods
AU5158000A (en) Novel therapeutic use of viral inflammation modulatory protein in blocking xenograft rejection
WO2001074401A3 (en) Camptothecin complexes
HK1085744A1 (en) Steroid compounds with anti-tumor activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/4-4/4, DRAWINGS, REPLACED BY NEW PAGES 1/4-4/4; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

ENP Entry into the national phase

Ref document number: 2371728

Country of ref document: CA

Ref country code: CA

Ref document number: 2371728

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 502887

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 10014335

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2000944644

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000944644

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642